BML-280
CAT:
804-HY-114095-03
Size:
10 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
BML-280
- CAS Number: 1158347-73-9
- UNSPSC Description: BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].
- Target Antigen: Interleukin Related; Phospholipase; TNF Receptor
- Type: Reference compound
- Related Pathways: Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease
- Field of Research: Cancer; Metabolic Disease; Inflammation/Immunology
- Assay Protocol: https://www.medchemexpress.com/bml-280.html
- Purity: 99.64
- Solubility: DMSO : 125 mg/mL (ultrasonic)
- Smiles: O=C(C1=CC2=CC=CC=C2N=C1)NCCN(CC3)CCC3(N(C4=CC=CC=C4)CN5)C5=O
- Molecular Weight: 429.51
- References & Citations: [1]Burkhardt U, et al. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. |[2]Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257.|[3]Tsai YR, et al. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):507-19.
- Shipping Conditions: Blue Ice
- Storage Conditions: -20°C, 3 years (Powder)
- Clinical Information: No Development Reported